BROOMFIELD, CO - 
(NewMediaWire) - April 23, 2024 - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11 am PT. Brent Ness, CEO of Aclarion, Inc. will be hosting the presentation and answering questions at the conclusion.
To access the live presentation, please use the following information:
Planet MicroCap Showcase: VEGAS 2024
Date: Wednesday, May 1, 2024
Time: 11 am PT
Webcast: https://www.webcaster4.com/Webcast/Page/3026/50174
If you would like to book a 1x1 investor meeting and to attend the Planet MicroCap Showcase: VEGAS 2024, please make sure you are registered here: https://planetmicrocapshowcase.com/signup
1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV
The Planet MicroCap Showcase: VEGAS 2024 website is available here: https://planetmicrocapshowcase.com/
If you can’t make the live presentation, all company presentations “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda”: https://planetmicrocapshowcase.com/agenda
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
